Exelon patch rivastigmine tartrate is a reversible cholinesterase inhibitor by Ray Sahelian, M.D.

Pathological changes in dementia of the Alzheimer’s type and dementia associated with Parkinson’s disease involve cholinergic neuronal pathways that project from the basal forebrain to the cerebral cortex and hippocampus. These pathways are thought to be intricately involved in memory, attention, learning, and other cognitive processes. While the precise mechanism of rivastigmine's action is unknown, it is postulated to exert its therapeutic effect by enhancing cholinergic function.

Exelon (rivastigmine tartrate, Novartis) is a prescription medication pproved by the FDA for the treatment of mild-to-moderate dementia (chronic loss or impairment of intellectual capacity) associated with Parkinson's disease.